www.fdanews.com/articles/161252-alexion-faces-potential-25-million-charge-from-recall
Alexion Faces Potential $25 Million Charge From Recall
December 20, 2013
Alexion’s recall and replacement of vials of its rare disease drug Soliris could cost the company between $10 and $25 million in the fourth quarter, the drugmaker says in a recent SEC filing. The recall and replacement was prompted by the presence of visible particles observed as part of Alexion’s periodic testing of retained samples.
Drug GMP Report
Drug GMP Report